Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning […]
February 2014 Life Science Industry Research Reports
PharmaPoint: Schizophrenia – Japan Drug Forecast and Market Analysis to 2022
Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning […]
PharmaPoint: Schizophrenia – 5EU Drug Forecast and Market Analysis to 2022
Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning […]
PharmaPoint: Schizophrenia – US Drug Forecast and Market Analysis to 2022
Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning […]
PharmaPoint: Ulcerative Colitis – Global Drug Forecast and Market Analysis to 2022
During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients […]
PharmaPoint: Schizophrenia – Current and Future Players
GlobalData has released its pharma report, “PharmaPoint: Schizophrenia Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Schizophrenia Market. The report identifies and analyses the key […]
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2013
GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals Q4 2013” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report […]
Medical Equipment Monthly Deals Analysis: January 2014- M&A and Investment Trends
GlobalData’s “Medical Equipment Monthly Deals Analysis: January 2014M&A and Investment Trends” report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the medical equipment industry. The report provides detailed information on […]
Indolent Lymphoma Global Clinical Trials Review, H1, 2014
GlobalData’s clinical trial report, “Indolent Lymphoma Global Clinical Trials Review, H1, 2014” provides data on the Indolent Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Indolent Lymphoma. It includes an overview […]
Leiomyosarcoma Global Clinical Trials Review, H1, 2014
GlobalData’s clinical trial report, “Leiomyosarcoma Global Clinical Trials Review, H1, 2014” provides data on the Leiomyosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Leiomyosarcoma. It includes an overview of the trial […]